Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(50.0%)
Phase 2
3(50.0%)
6Total
Phase 1(3)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00378495Phase 1Terminated

Miltefosine for Brazilian Visceral Leishmaniasis

Role: lead

NCT01635777Phase 2Completed

Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)

Role: lead

NCT01380301Phase 2Terminated

Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony

Role: collaborator

NCT00373568Phase 1Completed

Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

Role: lead

NCT00233545Phase 2Completed

Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia

Role: lead

NCT00373776Phase 1Completed

Miltefosine for Mucosal Leishmaniasis

Role: lead

All 6 trials loaded